PURPOSE: To investigate whether intensity-modulated proton therapy with a reduced spot size (rsIMPT) could further reduce the parotid and submandibular gland dose compared with previously calculated IMPT plans with a larger spot size. In addition, it was investigated whether the obtained dose reductions would theoretically translate into a reduction of normal tissue complication probabilities (NTCPs). METHODS: Ten patients with N0 oropharyngeal cancer were included in a comparative treatment planning study. Both IMPT plans delivered simultaneously 70 Gy to the boost planning target volume (PTV) and 54 Gy to the elective nodal PTV. IMPT and rsIMPT used identical three-field beam arrangements. In the IMPT plans, the parotid and submandibular salivary glands were spared as much as possible. rsIMPT plans used identical dose-volume objectives for the parotid glands as those used by the IMPT plans, whereas the objectives for the submandibular glands were tightened further. NTCPs were calculated for salivary dysfunction and xerostomia. RESULTS: Target coverage was similar for both IMPT techniques, whereas rsIMPT clearly improved target conformity. The mean doses in the parotid glands and submandibular glands were significantly lower for three-field rsIMPT (14.7 Gy and 46.9 Gy, respectively) than for three-field IMPT (16.8 Gy and 54.6 Gy, respectively). Hence, rsIMPT significantly reduced the NTCP of patient-rated xerostomia and parotid and contralateral submandibular salivary flow dysfunction (27%, 17%, and 43% respectively) compared with IMPT (39%, 20%, and 79%, respectively). In addition, mean dose values in the sublingual glands, the soft palate and oral cavity were also decreased. Obtained dose and NTCP reductions varied per patient. CONCLUSIONS: rsIMPT improved sparing of the salivary glands and reduced NTCP for xerostomia and parotid and submandibular salivary dysfunction, while maintaining similar target coverage results. It is expected that rsIMPT improves quality of life during and after radiotherapy treatment.
PURPOSE: To investigate whether intensity-modulated proton therapy with a reduced spot size (rsIMPT) could further reduce the parotid and submandibular gland dose compared with previously calculated IMPT plans with a larger spot size. In addition, it was investigated whether the obtained dose reductions would theoretically translate into a reduction of normal tissue complication probabilities (NTCPs). METHODS: Ten patients with N0 oropharyngeal cancer were included in a comparative treatment planning study. Both IMPT plans delivered simultaneously 70 Gy to the boost planning target volume (PTV) and 54 Gy to the elective nodal PTV. IMPT and rsIMPT used identical three-field beam arrangements. In the IMPT plans, the parotid and submandibular salivary glands were spared as much as possible. rsIMPT plans used identical dose-volume objectives for the parotid glands as those used by the IMPT plans, whereas the objectives for the submandibular glands were tightened further. NTCPs were calculated for salivary dysfunction and xerostomia. RESULTS: Target coverage was similar for both IMPT techniques, whereas rsIMPT clearly improved target conformity. The mean doses in the parotid glands and submandibular glands were significantly lower for three-field rsIMPT (14.7 Gy and 46.9 Gy, respectively) than for three-field IMPT (16.8 Gy and 54.6 Gy, respectively). Hence, rsIMPT significantly reduced the NTCP of patient-rated xerostomia and parotid and contralateral submandibular salivary flow dysfunction (27%, 17%, and 43% respectively) compared with IMPT (39%, 20%, and 79%, respectively). In addition, mean dose values in the sublingual glands, the soft palate and oral cavity were also decreased. Obtained dose and NTCP reductions varied per patient. CONCLUSIONS: rsIMPT improved sparing of the salivary glands and reduced NTCP for xerostomia and parotid and submandibular salivary dysfunction, while maintaining similar target coverage results. It is expected that rsIMPT improves quality of life during and after radiotherapy treatment.
Authors: Blake Smith; Edgar Gelover; Alexandra Moignier; Dongxu Wang; Ryan T Flynn; Liyong Lin; Maura Kirk; Tim Solberg; Daniel E Hyer Journal: Med Phys Date: 2016-08 Impact factor: 4.071
Authors: Alexandra Moignier; Edgar Gelover; Blake R Smith; Dongxu Wang; Ryan T Flynn; Maura L Kirk; Liyong Lin; Timothy D Solberg; Alexander Lin; Daniel E Hyer Journal: Med Phys Date: 2016-03 Impact factor: 4.071
Authors: Maryam Moteabbed; Torunn I Yock; Nicolas Depauw; Thomas M Madden; Hanne M Kooy; Harald Paganetti Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-29 Impact factor: 7.038
Authors: Nicholas P Nelson; Wesley S Culberson; Daniel E Hyer; Blake R Smith; Ryan T Flynn; Patrick M Hill Journal: Biomed Phys Eng Express Date: 2022-02-18
Authors: Theodore J Geoghegan; Nicholas P Nelson; Ryan T Flynn; Patrick M Hill; Suresh Rana; Daniel E Hyer Journal: Med Phys Date: 2020-04-06 Impact factor: 4.071
Authors: Laura S Sasportas; Drew N Hosford; Maria A Sodini; Dale J Waters; Elizabeth A Zambricki; Joëlle K Barral; Edward E Graves; Todd J Brinton; Paul G Yock; Quynh-Thu Le; Davud Sirjani Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2013-05-03
Authors: Alexandra Moignier; Edgar Gelover; Dongxu Wang; Blake Smith; Ryan Flynn; Maura Kirk; Liyong Lin; Timothy Solberg; Alexander Lin; Daniel Hyer Journal: Int J Part Ther Date: 2016-03-24
Authors: Nicholas P Nelson; Wesley S Culberson; Daniel E Hyer; Theodore J Geoghegan; Kaustubh A Patwardhan; Blake R Smith; Ryan T Flynn; Jen Yu; Suresh Rana; Alonso N Gutiérrez; Patrick M Hill Journal: Med Phys Date: 2021-04-09 Impact factor: 4.506
Authors: Houda Bahig; Brandon G Gunn; Adam S Garden; Rong Ye; Kate Hutcheson; David I Rosenthal; Jack Phan; Clifton D Fuller; William H Morrison; Jay Paul Reddy; Sweet Ping Ng; Neil D Gross; Erich M Sturgis; Renata Ferrarotto; Maura Gillison; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25